The cost of multiple sclerosis in Norway

European Journal of Health Economics

Volumn 13, Issue 1, 2012, Pages 81-91

  Svendsen, B ^a   Myhr, K M ^b,c   Nyland, H ^b   Aarseth, J H ^b  

^a NORWEGIAN SCHOOL OF ECONOMICS   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cost of illness; EDSS; Multiple sclerosis; Norway; Quality of life; Relapse

Indexed keywords

ADULT; ARTICLE; COST OF ILLNESS; DISEASE SEVERITY; EUROPE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NORWAY; PRIORITY JOURNAL; QUALITY OF LIFE; RETIREMENT; SWEDEN;

ADULT; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NORWAY; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84858705516     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0286-7     Document Type: Article

References (25)

1. McDonald, I., Compston, A.: The symptoms and signs of multiple scleroses. In: Compston, A. et al. (eds.) McAlpine's Multiple Sclerosis, 4 ed, Elsevier (2006)
2. Weinshenker, B.G., Bass, B., Rice, G.P.A., Noseworthy, J., Carriere, W., Baskerville, J., et al.: The natural history of multiple sclerosis: a geographically base study. I: clinical course and disability. Brain 112, 133-146 (1989)
3. Bourdette, D.N., Prochazaka, A.V., Mitchell, W., Licari, P., Burks, J.: Health care costs of veterans with MS: implications for the rehabilitation of MS. Arch. Phys. Med. Rehabil. 73, 25 (1993)
4. The Canadian Burden of Illness Study Group: Burden of illness of multiple sclerosis. Part I: cost of illness. Can. J. Neurol. Sci. 25, 23-30 (1998)
5. Carton, H., Loos, R., Pacolet, J., Versieck, K., Vlietinck, R.: Utilization and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J. Neurol. Neurosurg. Psychiatry 64, 444-450 (1998)
6. McCormac, P.L., Scott, L.J.: Interferon-β-1b - a review of its use in relapsing-remitting and secondary progressive multiple scleroses. CNS Drugs 18(8), 521-546 (2004)
7. Kappos, L.: Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult. Scler. 10, 46-55 (2004)
8. Henriksson, F., Fredrikson, S., Masterman, T., Jönsson, T.: Costs, quality of life and disease severity in multiple sclerosis: a crosssectional study in Sweden. Eur. J. Neurol. 8, 27-35 (2001)
9. Kobelt, G., Lindgren, P., Smala, A., Jônsson, B., Group GCoMS: Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur. J. Health Econ. 2, 60-68 (2001)
10. The EuroQol Group: EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16, 199-208 (1990)
11. Kurtzke, J.F.: Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444-1452 (1983)
12. Drummond, F.M., O'Brien, B., Stoddard, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications, New York (2003)
13. Grytten, N., Glad, S.B., Aarseth, J.H., Nyland, H., Midgard, R., Myhr, K.-M.: A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 66, 182-186 (2006)
14. Torkildsen, Ø., Grytten, N., Myhr, K.-M.: Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurol. Scand. Suppl. 187, 46-50 (2007)
15. Poser, C.M., Paty, D.W., Scheinberg, L.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neirol. 14, 227-231 (1983)
16. Szende, A., Oppe, M., Devlin, N.: EQ-5D value sets - inventory, comparative review and user guide. EuroQol Group Monographs, vol. 2. Springer, 2007
17. Kind, P., Dolan, P., Gudex, C., Williams, A.: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316(7133), 736-774 (1998)
18. Patwardahn, M.B., Mathcar, D.B., Samsa, G.P., McCrory, D.C., Williams, D.G., Li, T.T.: Cost of multiple sclerosis by level of disability; a review of literature. Mult. Scler. 11, 232-239 (2005)
19. World Health Organization: WHO guide to identifying the economic consequences of disease and injury, WHO 2009
20. Koopmanschap, M., Rutten, F., Vaninveld, B., Vanroijen, L.: The friction cost method for measuring indirect costs of disease. J. Health Econ. 14, 171-189 (1995)
21. Manns, B., Meltzer, D., Taub, K., Donaldson, C.: Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ. 12(11), 949-958 (2003)
22. Berg, J., Lindgren, P., Fredrikson, S., Kobelt, G.: Costs and quality of life of multiple sclerosis in Sweden. Eur. J. Health Econ. 7, s75-s85 (2006)
23. Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., Jönsson, B.: Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 77, 918-926 (2006)
24. Kobelt, G., Berg, J., Lindgren, P., Jönsson, B.: Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur. J. Health Econ. 7, S5-S13 (2006)
25. Kobelt, G., Pugliatti, M.: Cost of multiple sclerosis in Europe. Eur. J. Neurol. 12(Suppl. 1), 63-67 (2005)